JOHN W ANGERS
Medical Practice in Tinton Falls, NJ
License number
New Jersey 25MA02809600
Expiration Date
Jun 30, 2003
Category
Medical Examiners
Type
Medical Doctor
Address
Address
Tinton Falls, NJ
Personal information
See more information about JOHN W ANGERS at radaris.comName
Address
Phone
5 Hilltop Ter N, Red Bank, NJ 07701
Professional information
Methodology For The Immunodiagnosis Of Multiple Sclerosis And/Or Malignant Diseases From Blood Sample Analysis
US Patent:
4311686, Jan 19, 1982
Filed:
Apr 30, 1979
Appl. No.:
6/087024
Inventors:
John W. Angers - Red Bank NJ
Lazar Korik - Brooklyn NY
Lazar Korik - Brooklyn NY
Assignee:
The Immunology Development Corporation - Red Bank NJ
International Classification:
G01N 3354, G01N 3356, C07G 700
US Classification:
424 1
Abstract:
New and improved methodology for the diagnosis of a disease from blood sample analysis is disclosed and comprises: the preparation of a putative antigenic body substance extract, which is specific to disease-sensitized blood leukocytes, from the pooled, like body substances of a plurality of donors known to have the disease of interest; the mixture of said extract with the blood sample leukocytes; the promotion of the reaction therebetween to modify a characteristic of the disease-sensitized leukocytes, if any, of the blood sample; and the determination of the extent, if any, to which said characteristic has been modified. In multiple sclerosis diagnosis, said body substance may be blood or urine; while for malignant disease (for example breast cancer, or cancer of the head and neck) said body substance may be blood, urine, pleural fluid, ascites fluid, supernates of tumor cells or tumor cells grown in culture media.
Human Immune Factors And Processes For Their Production And Use
US Patent:
4618494, Oct 21, 1986
Filed:
Jul 20, 1984
Appl. No.:
6/632705
Inventors:
John W. Angers - Red Bank NJ
Assignee:
Immunology Development Corporation - Red Bank NJ
International Classification:
A61K 3514
US Classification:
424101
Abstract:
Type 1 Diabetes and other virus-induced or autoimmunological diseases are treated with Human Immune Factors. These Human Immune Factors are extracted from blood cells by activating said blood cells with human lymphoblastoid interferon-alpha or staphage lysate or other activator or combination of activators. Human Immune Factors are purified and made suitable for pharmaceutical use by isolating compounds with molecular weights between about 1,000 and about 25,000 daltons.